Coe Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | $2.71M | Sell |
24,071
-644
| -3% | -$72.5K | 2.56% | 11 |
|
|
2021
Q1 | $2.67M | Sell |
24,715
-515
| -2% | -$55.1K | 2.69% | 10 |
|
|
2020
Q4 | $2.7M | Sell |
25,230
-339
| -1% | -$32.6K | 2.95% | 10 |
|
|
2020
Q3 | $2.24M | Buy |
25,569
+1,067
| +4% | +$100K | 3.01% | 7 |
|
|
2020
Q2 | $2.41M | Buy |
24,502
+351
| +1% | +$30.9K | 3.58% | 5 |
|
|
2020
Q1 | $1.84M | Buy |
24,151
+391
| +2% | +$33.3K | 3.07% | 11 |
|
|
2019
Q4 | $2.1M | Sell |
23,760
-2,676
| -10% | -$222K | 2.69% | 12 |
|
|
2019
Q3 | $2M | Buy |
26,436
+441
| +2% | +$30.2K | 2.22% | 14 |
|
|
2019
Q2 | $1.89M | Buy |
25,995
+1,757
| +7% | +$138K | 2.09% | 15 |
|
|
2019
Q1 | $1.95M | Sell |
24,238
-3,260
| -12% | -$267K | 2.27% | 11 |
|
|
2018
Q4 | $2.54M | Sell |
27,498
-28
| -0.1% | -$2.46K | 3.11% | 5 |
|
|
2018
Q3 | $2.6M | Buy |
27,526
+1,704
| +7% | +$162K | 2.57% | 8 |
|
|
2018
Q2 | $2.39M | Sell |
25,822
-160
| -0.6% | -$15.6K | 2.66% | 7 |
|
|
2018
Q1 | $2.46M | Sell |
25,982
-155
| -0.6% | -$17K | 2.67% | 7 |
|
|
2017
Q4 | $2.53M | Sell |
26,137
-3,210
| -11% | -$303K | 2.67% | 7 |
|
|
2017
Q3 | $2.61M | Sell |
29,347
-495
| -2% | -$37.7K | 2.71% | 4 |
|
|
2017
Q2 | $2.16M | Sell |
29,842
-190
| -0.6% | -$12.8K | 2.46% | 7 |
|
|
2017
Q1 | $1.96M | Sell |
30,032
-385
| -1% | -$24.2K | 2.36% | 8 |
|
|
2016
Q4 | $1.91M | Sell |
30,417
-88
| -0.3% | -$5.37K | 2.46% | 7 |
|
|
2016
Q3 | $1.92M | Buy |
30,505
+1,890
| +7% | +$122K | 0.62% | 49 |
|
|
2016
Q2 | $1.77M | Buy |
28,615
+275
| +1% | +$16.8K | 0.61% | 53 |
|
|
2016
Q1 | $1.62M | Buy |
28,340
+1,885
| +7% | +$105K | 0.52% | 65 |
|
|
2015
Q4 | $1.57M | Sell |
26,455
-1,196
| -4% | -$68.9K | 0.62% | 50 |
|
|
2015
Q3 | $1.5M | Sell |
27,651
-270
| -1% | -$17.6K | 0.56% | 56 |
|
|
2015
Q2 | $1.88M | Buy |
27,921
+7,300
| +35% | +$477K | 0.68% | 46 |
|
|
2015
Q1 | $1.21M | Sell |
20,621
-6,015
| -23% | -$363K | 0.49% | 69 |
|
|
2014
Q4 | $1.74M | Buy |
26,636
+2,150
| +9% | +$136K | 0.56% | 56 |
|
|
2014
Q3 | $1.41M | Buy |
24,486
+800
| +3% | +$44.4K | 0.53% | 62 |
|
|
2014
Q2 | $1.34M | Sell |
23,686
-465
| -2% | -$24.4K | 0.48% | 73 |
|
|
2014
Q1 | $1.24M | Buy |
24,151
+1,988
| +9% | +$100K | 0.36% | 99 |
|
|
2013
Q4 | $1.17M | Buy |
+22,163
| New | +$1.09M | 0.41% | 79 |
|
|
2013
Q3 | – | Sell |
-23,396
| Closed | -$967K | – | 109 |
|
|
2013
Q2 | $967K | Buy |
+23,396
| New | +$1.02M | 0.37% | 87 |
|
Other funds holding ABBV
Coe Capital Management's ABBV Position: Q2 2021 in Review
Coe Capital Management reduced its AbbVie (ABBV) stake by 2.6% in Q2 2021, selling an estimated $72.5K and leaving 24,071 shares worth $2.71M. The position accounts for 2.56% of the portfolio, ranked #11.
Coe Capital Management first reported a position in ABBV in Q2 2013 and has held it in 32 quarters since. 2,676 funds tracked by Wall St. Rank hold ABBV as of Q2 2021.
- Coe Capital Management held 24,071 shares of AbbVie worth $2.71M as of Q2 2021.
- Coe Capital Management sold 644 AbbVie shares in Q2 2021, an estimated $72.5K.
- AbbVie made up 2.56% of Coe Capital Management's portfolio in Q2 2021, its #11 holding.
- Coe Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 32 quarters since.
- 2,676 funds tracked by Wall St. Rank held AbbVie as of Q2 2021.
Based on Coe Capital Management's 13F filing for Q2 2021, filed 22 Jul 2021.